Wechselwirkungen · Prevymis
PREVYMIS 240 mg concentrate for solution for infusion PREVYMIS 480 mg concentrate for solution for infusion · Abschnitt 4.5 · PDF-Seite 49
HOS-139897 · Präparat HOS-098408
Interaction not studied. Expected: ↔ letermovir Wakefulness-promoting agents modafinil Interaction not studied. Modafinil may decrease plasma Expected: concentrations of letermovir. ↓ letermovir Co-administration of letermovir and modafinil is not recommended. (P-gp/UGT induction) * This table is not all inclusive. † ↓ =decrease, ↑ =increase ↔ =no clinically relevant change ‡ One-way interaction study assessing the effect of letermovir on the concomitant medicinal product. § These data are the effect of rifampicin on letermovir 24 hours after final rifampicin dose. # Refer to the respective prescribing information.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): modafinil (HOS-090546)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-12-12T02:00:00Z · SHA-256 db4998a6cb590006789107af9f09c4196d815ed441a57d076042c2223b8d34a9 · Passage 9b62edaa5854fccf9f52e13b09950286019d417a8e3ec89a5ab1395346bf2571 · Zeichen 39288–40185 im Abschnitt